Skip to main
MLYS

MLYS Stock Forecast & Price Target

MLYS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Mineralys Therapeutics Inc. is focusing on the development of lorundrostat, which demonstrates a strong potential in treating uncontrolled and resistant hypertension, showcasing a compelling placebo-adjusted blood pressure benefit exceeding 10mmHg. Recent insights from Key Opinion Leaders (KOLs) support the differentiated profile of lorundrostat, highlighting its robust effects across targeted patient populations and the anticipated positive FDA feedback leading to an NDA submission. Furthermore, there is an increased estimate of patients seeking innovative treatment, rising from 10% to 12% among diagnosed uncontrolled hypertension patients, indicating a growing market opportunity for lorundrostat in addressing significant unmet medical needs.

Bears say

Mineralys Therapeutics Inc faces significant risks that impact its investment outlook, particularly concerning the commercial potential of its lead product candidate, lorundrostat. The company's ability to achieve projected peak commercial revenues is hindered by uncertainties in market size, penetration rates, and pricing strategies. Additionally, the failure to secure adequate capital resources for operations and the ongoing challenges associated with program development and commercialization contribute to a negative financial outlook for the company.

MLYS has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Mineralys Therapeutics Inc (MLYS) Forecast

Analysts have given MLYS a Buy based on their latest research and market trends.

According to 6 analysts, MLYS has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Mineralys Therapeutics Inc (MLYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.